{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:45:04Z","timestamp":1791254704065,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["71503015"],"award-info":[{"award-number":["71503015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>China has emerged as a powerful platform for global pharmaceutical research and development (R&amp;D) amid the 2014 Ebola outbreak. The research and development impact of developing countries on prevention and control of infectious disease outbreaks has long been underestimated, particularly for emerging economies like China. Here, we studied its research and development progress and government support in response to Ebola outbreak by timeline, input, and output at each research and development stage. This study will contribute to a deeper understanding of the research and development gaps and challenges faced by China, as well as providing evidence-based suggestions on how to accelerate the drug development process to meet urgent needs during future outbreaks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were obtained from the National Nature Science Foundation of China database, PubMed database, Patent Search System of the State Intellectual Property Office of China, National Medical Products Administration, national policy reports and literature between Jan 1st, 2006 and Dec 31st, 2017. An overview of research funding, research output, pharmaceutical product patent, and product licensed was described and analyzed by Microsoft Excel. A descriptive analysis with a visualization of plotting charts and graphs was conducted by reporting the mean\u2009\u00b1\u2009standard deviation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>China has successfully completed the research and development of the Ebola Ad5-EBOV vaccine within 26\u2009months, while the preparation and implementation of clinical trials took relative long time. The National Nature Science Foundation of China funded CNY 44.05 million (USD 6.27 million) for Ebola-related researches and committed strongly to the phase of basic research (87.8%). A proliferation of literature arose between 2014 and 2015, with a 1.7-fold increase in drug research and a 2.5-fold increase in diagnostic research within 1\u00a0year. Three years on from the Ebola outbreak, six Ebola-related products in China were approved by the National Medical Products Administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>China has started to emphasize the importance of medical product innovation as one of the solutions for tackling emerging infectious diseases. Continuing research on the development of regulatory and market incentives, as well as a multilateral collaboration mechanism that unifies cross-channel supports, would advance the process for China to enter global R&amp;D market more effectively.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40249-020-00643-0","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T17:02:57Z","timestamp":1584032577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges and opportunities for China entering global research and development for emerging infectious diseases: a case study from Ebola experience"],"prefix":"10.1186","volume":"9","author":[{"given":"Chao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Mu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"643_CR1","unstructured":"Center for Disease Control. Ebola Outbreak in West Africa Case Counts. https:\/\/www.cdc.gov\/vhf\/ebola\/outbreaks\/2014-west-africa\/case- counts.html. Accessed 20 Oct 2018."},{"key":"643_CR2","unstructured":"World Health Organization. Ebola virus. http:\/\/www.who.int\/csr\/disease\/ebola\/zh\/. Accessed 21 Dec 2018."},{"key":"643_CR3","volume-title":"UN senior leaders outline needs for global Ebola response","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. UN senior leaders outline needs for global Ebola response. Geneva: WHO; 2014."},{"issue":"7519","key":"643_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/513469a","volume":"513","author":"D Butler","year":"2014","unstructured":"Butler D. Global Ebola response kicks into gear at last. Nature. 2014;513(7519):469.","journal-title":"Nature."},{"issue":"9942","key":"643_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0140-6736(14)61322-2","volume":"384","author":"A Green","year":"2014","unstructured":"Green A. WHO and partners launch Ebola response plan. Lancet. 2014;384(9942):481.","journal-title":"Lancet."},{"key":"643_CR6","volume-title":"Ebola R&D. Landscape of clinical candidates and trials","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Ebola R&D. Landscape of clinical candidates and trials. Geneva: WHO; 2015."},{"issue":"10174","key":"643_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy D, McElroy AK, de Clerck H, G\u00fcnther S, van Griensven J. Ebola virus disease. Lancet. 2019;393(10174):936\u201348.","journal-title":"Lancet."},{"key":"643_CR8","volume-title":"WHO Ebola R&D Effort \u2013 vaccines, therapies, diagnostics","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO Ebola R&D Effort \u2013 vaccines, therapies, diagnostics.2019. https:\/\/www.who.int\/medicines\/ebola-treatment\/ebola_r_d_effort\/en\/. Accessed 27 Dec 2018."},{"key":"643_CR9","first-page":"366","volume":"13","author":"O Dyer","year":"2019","unstructured":"Dyer O. Two Ebola treatments halve deaths in trial in DRC outbreak. BMJ. 2019;13:366.","journal-title":"BMJ."},{"key":"643_CR10","unstructured":"World Health Organization. Essential medicine and health products. 2015. http:\/\/www.who.int\/medicines\/ebola-treatment\/emp_ebola_therapies\/en\/. Accessed 27 Dec 2018."},{"key":"643_CR11","unstructured":"World Health Organization. WHO supports Ebola vaccination of high risk populations in the Democratic Republic of the Congo. https:\/\/www.who.int\/news-room\/detail\/21-05-2018-who-supports-ebola-vaccination-of-high-risk-populations-in-the-democratic-republic-of-the-congo. Accessed 27 Dec 2018."},{"key":"643_CR12","unstructured":"World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf. Accessed 27 July 2019."},{"issue":"3\u20134","key":"643_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.techsoc.2008.05.001","volume":"30","author":"Z Zhu","year":"2008","unstructured":"Zhu Z, Gong X. Basic research: its impact on China's future. Technol Soc. 2008;30(3\u20134):293\u20138.","journal-title":"Technol Soc"},{"key":"643_CR14","doi-asserted-by":"publisher","first-page":"26943","DOI":"10.1038\/srep26943","volume":"6","author":"M Yang","year":"2016","unstructured":"Yang M, Ke Y, Wang X, Ren H, Liu W, Lu H, et al. Development and evaluation of a rapid and sensitive EBOV-RPA test for rapid diagnosis of Ebola virus disease. Sci Rep. 2016;6:26943.","journal-title":"Sci Rep"},{"issue":"1","key":"643_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1017\/dmp.2014.152","volume":"9","author":"HJ Fan","year":"2015","unstructured":"Fan HJ, Gao HW, Ding H, Zhang BK, Hou SK. The Ebola threat: China\u2019s response to the west African epidemic and national development of prevention and control policies and infrastructure. Disaster Med Public. 2015;9(1):64\u20135.","journal-title":"Disaster Med Public"},{"issue":"2","key":"643_CR16","doi-asserted-by":"publisher","first-page":"020703","DOI":"10.7189\/jogh.06.020703","volume":"6","author":"JR Fitchett","year":"2016","unstructured":"Fitchett JR, Lichtman A, Soyode DT, Low A, de Onis JV, Head MG, et al. Ebola research funding: a systematic analysis, 1997\u20132015. J Glob Health. 2016;6(2):020703.","journal-title":"J Glob Health"},{"issue":"12","key":"643_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ijpara.2014.07.010","volume":"44","author":"DL Doolan","year":"2014","unstructured":"Doolan DL, Apte SH, Proietti C. Genome-based vaccine design: the promise for malaria and other infectious diseases. Int J Parasitol. 2014;44(12):901\u201313.","journal-title":"Int J Parasitol"},{"issue":"suppl_2","key":"643_CR18","doi-asserted-by":"publisher","first-page":"W783","DOI":"10.1093\/nar\/gki470","volume":"33","author":"A Doms","year":"2005","unstructured":"Doms A, Schroeder M. GoPubMed: exploring PubMed with the gene ontology. Nucleic Acids Res. 2005;33(suppl_2):W783\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"643_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40249-016-0154-5","volume":"5","author":"Q Wang","year":"2016","unstructured":"Wang Q, Zhou WM, Zhang Y, Wang HY, Du HJ, Nie K, et al. Good laboratory practices guarantee biosafety in the Sierra Leone-China friendship biosafety laboratory. Infect Dis Poverty. 2016;5(1):62.","journal-title":"Infect Dis Poverty"},{"key":"643_CR20","volume-title":"China developed an Ebola vaccin","author":"People\u2019s Republic of China Ministry of Commerce","year":"2016","unstructured":"People\u2019s Republic of China Ministry of Commerce. China developed an Ebola vaccin.2016.http:\/\/www.mofcom.gov.cn\/article\/i\/jyjl\/k\/201612\/20161202425318.shtml. Accessed 27 July 2019."},{"key":"643_CR21","volume-title":"Seventy-nine days of critical review, interpretation of the great power","author":"Center for drug evaluation, CFDA","year":"2017","unstructured":"Center for drug evaluation, CFDA. Seventy-nine days of critical review, interpretation of the great power. 2017. http:\/\/www.cde.org.cn\/news.do?method=viewInfoCommon&id=314241. Accessed 27 July 2019."},{"issue":"6996","key":"643_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature02759","volume":"430","author":"DM Morens","year":"2004","unstructured":"Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;430(6996):242.","journal-title":"Nature."},{"issue":"11","key":"643_CR23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3201\/eid2111.150949","volume":"21","author":"TR Frieden","year":"2015","unstructured":"Frieden TR, Damon IK. Ebola in West Africa\u2014CDC\u2019s role in epidemic detection, control, and prevention. Emerg Infect Dis. 2015;21(11):1897.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"643_CR24","first-page":"290","volume":"7","author":"L Yao","year":"2013","unstructured":"Yao L, Chen E, Chen Z, Gong Z. From SARS to H7N9: the mechanism of responding to emerging communicable diseases has made great progress in China. Biosci Trends. 2013;7(6):290\u20133.","journal-title":"Biosci Trends"},{"key":"643_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.coviro.2016.03.008","volume":"17","author":"AM Henao-Restrepo","year":"2016","unstructured":"Henao-Restrepo AM, Preziosi MP, Wood D, Moorthy V, Kieny MP. On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014\u20132016 Ebola epidemic in West Africa. Curr Opin Virol. 2016;17:138\u201344.","journal-title":"Curr Opin Virol"},{"issue":"10009","key":"643_CR26","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(15)00946-0","volume":"386","author":"S Moon","year":"2015","unstructured":"Moon S, Sridhar D, Pate MA, Jha AK, Clinton C, Delaunay S, et al. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM independent panel on the global response to Ebola. Lancet. 2015;386(10009):2204\u201321.","journal-title":"Lancet."},{"issue":"9","key":"643_CR27","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1080\/21645515.2018.1442161","volume":"14","author":"MP Kieny","year":"2018","unstructured":"Kieny MP. Lessons learned from Ebola Vaccine R&D during a public health emergency. Hum Vaccin Immunother. 2018;14(9):2114\u20135.","journal-title":"Hum Vaccin Immunother"},{"key":"643_CR28","unstructured":"Pharmaceutical Public-Private Partnerships in the United States and Europe: Moving from the Bench to the Bedside. https:\/\/digitalcommons.law.yale.edu\/cgi\/viewcontent.cgi?referer=https:\/\/www.google.com.hk\/&httpsredir=1&article=1011&context=ylas. Accessed 27 July 2019."},{"issue":"1","key":"643_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hs.2015.0001","volume":"13","author":"C Boddie","year":"2015","unstructured":"Boddie C. Federal funding in support of Ebola medical countermeasures R&D. Health Secur. 2015;13(1):3\u20138.","journal-title":"Health Secur"},{"key":"643_CR30","volume-title":"National Science and Technology Major Project","author":"Ministry of Science and Technology of the People\u2019s Republic of China","year":"2017","unstructured":"Ministry of Science and Technology of the People\u2019s Republic of China. National Science and Technology Major Project. 2017. http:\/\/www.most.gov.cn\/eng\/. Accessed 27 July 2019."},{"issue":"Suppl_1","key":"643_CR31","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.trstmh.2005.06.003","volume":"99","author":"S Nwaka","year":"2005","unstructured":"Nwaka S. Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. Trans R SocTrop Med Hyg. 2005;99(Suppl_1):S20\u20139.","journal-title":"Trans R SocTrop Med Hyg"},{"key":"643_CR32","volume-title":"NIAID\u2019s role in the United States government (USG) research response to the 2014\u201315 Ebola outbreak","author":"L Mcnay","year":"2015","unstructured":"L Mcnay. NIAID\u2019s role in the United States government (USG) research response to the 2014\u201315 Ebola outbreak. 2015. https:\/\/apha.confex.com\/apha\/143am\/webprogram\/Session45453.html. Accessed 27 July 2018."},{"key":"643_CR33","first-page":"735","volume":"79","author":"D Webber","year":"2001","unstructured":"Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ. 2001;79:735\u201341.","journal-title":"Bull World Health Organ"},{"key":"643_CR34","volume-title":"NIAID\u2019s role in the United States Government (USG) research response to the 2014\u201315 Ebola outbreak","author":"L Mcnay","year":"2017","unstructured":"L Mcnay. NIAID\u2019s role in the United States Government (USG) research response to the 2014\u201315 Ebola outbreak.2017. https:\/\/apha.confex.com\/apha\/143am\/webprogram\/Session45453.html. Accessed 27 July 2019."},{"issue":"1","key":"643_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1358\/dnp.2010.23.1.1441464","volume":"23","author":"P Cole","year":"2010","unstructured":"Cole P. Accelerating drug development and approval. Drug News Perspect. 2010;23(1):37\u201347.","journal-title":"Drug News Perspect"},{"issue":"10","key":"643_CR36","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/cid\/cix097","volume":"64","author":"JC Larsen","year":"2017","unstructured":"Larsen JC, Disbrow GL. Project BioShield and the biomedical advanced research development authority: a 10-year progress report on meeting us preparedness objectives for threat agents. Clin Infect Dis. 2017;64(10):1430\u20134.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"643_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1332\/030557317X14974484611316","volume":"46","author":"RA DeLeo","year":"2018","unstructured":"DeLeo RA. Indicators, agendas and streams: analysing the politics of preparedness. Policy Polit. 2018;46(1):27\u201345.","journal-title":"Policy Polit"},{"key":"643_CR38","unstructured":"Speech Made by Minister Bi Jingquan at the National Videophone Conference on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation. 2017. http:\/\/www.sdfda.gov.cn\/art\/2017\/10\/12\/art_5765_177628.html. Accessed 27 May 2018."}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-020-00643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40249-020-00643-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-020-00643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T16:37:50Z","timestamp":1666111070000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-020-00643-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1186\/s40249-020-00643-0","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}